Diligence memo · auto-generated · as of July 2, 2026
Xanodyne Pharmaceuticals Inc
Xanodyne Pharmaceuticals Inc has raised $132M over 3 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Xanodyne Pharmaceuticals Inc operates in Pharmaceuticals, based in NEWPORT.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Xanodyne Pharmaceuticals Inc has raised $132M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $88M on 2009-05-15.
Most recent recorded round closed around 2009-05-15.
Valuation (modeled)modeled
Provath models Xanodyne Pharmaceuticals Inc at approximately $3.1B (range $285M–$8.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 236 months.
Last raise 17.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 94% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Amarin Corp Plc\Uk, Ikaria Holdings Inc.
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.